No medical therapy has been shown to reduce the rate of restenosis following percutaneous transluminal coronary angioplasty. We examined the existing evidence for the use of omega-3 fatty acids in this capacity with the tool of meta-analysis.
A computerized search and a bibliographic review of published articles were performed. Abstracts were identified through journals, Index Medicus, and an unpublished listing of recent requests for fish oil for experimental use. All English-language randomized clinical trials with available reports were included in the analysis. The quality, design differences, and outcomes were evaluated for each study.
For four studies that used angiography to define coronary restenosis, the absolute difference in restenosis rates between treatment and control groups was 13.9% (95% confidence interval [CI], 3.2% to 24.5%). Furthermore, regression analysis revealed a positive linear relationship between the dose of omega-3 fatty acids used and the absolute difference in restenosis rates (r=.99, P<.03). When three studies that used stress testing as a means of determining restenosis rates were added to the four studies that used angiography, the risk difference was 5.1% (95% CI, —3.8% to 13.9%).
Restenosis after coronary angioplasty is reduced by supplemental fish oils, and the extent of the observed benefit may be dependent on the dose of omega-3 fatty acids used.(Arch Intern Med. 1993;153:1595-1601)
Gapinski JP, VanRuiswyk JV, Heudebert GR, Schectman GS. Preventing Restenosis With Fish Oils Following Coronary Angioplasty: A Meta-analysis. Arch Intern Med. 1993;153(13):1595–1601. doi:10.1001/archinte.1993.00410130117012
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.